Jul 2026
Abstract A088: SLC39A6-targeted combination therapy to reverse CAF-induced resistance in HER2+ breast cancer using a microfluidic platform
Findings identify SLC39A6 as a novel, actionable therapeutic target in CAF-rich HER2+ breast cancer and provide preclinical rationale for SLC39A6-directed ADC combination strategies, and establish a new paradigm for patient-specific drug screening in the context of the stromal tumor microenvironment.
Zeina S. Habli, Tiangyang Li, Mathew Poskus et al.
· Clinical Cancer Research · 0 citations